David L. Porter – VJRegenMed

Impact of COVID-19 on CAR T-cell therapies

admin_vjr_user — Thu, 08 Oct 2020 14:08:16 +0000

David L. Porter, MD, University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, explores the impact of the COVID-19 pandemic on the treatment and management of patients with hematological malignancies treated with CAR T-cell therapies, which are widely recognized as high-risk interventions. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

Anti-CD19 CAR T-cells for adults

admin_vjr_user — Thu, 08 Oct 2020 14:08:15 +0000

David L. Porter, MD, University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, outlines the use of CD-19 CAR T-cells for adults with lymphoma and leukemia, specifically discussing the sustained remissions seen in patients treated with tisagenlecleucel and axicabtagene ciloleucel. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

Long-term outcomes of anti-CD19 CAR-T in R/R CLL

admin_vjr_user — Thu, 08 Oct 2020 14:08:15 +0000

David L. Porter, MD, University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, explores the long-term outcomes from a randomized dose optimization study of CAR-modified T-cells in relapsed/refractory (R/R) chronic lymphoyctic leukemia (CLL). This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).